Posts for Ticker ‘DSCO’

Top Day Trader Alerts (ALL, MO, AIG, AXL, DSCO, GRMN)

These are this Friday’s top day trader alert stocks.  We have more color and more detail on price and volume analysis linked through to each at VSInvestor.com:

AllState Corp. (NYSE: ALL) is holding up better than we would have expected considering a Goldman Sachs downgrade to Sell.

Altria Group Inc. (NYSE: MO) had unbelievable options trading yesterday, although it appears to be a dividend capture trade… over 1 million SEPT-2009 contracts were traded yesterday on that basis.

American International Group, Inc. (NYSE: AIG) is holding up rather well considering the downgrade.  We have color on price channels and trading patterns on this one because of how sketchy this stock is.

American Axle (NYSE: AXL) is soaring by 17% on an upgrade, a rather tall task for a research call.

Discovery Laboratories Inc. (NASDAQ: DSCO) is up about 50% on an FDA review date.

Garmin Ltd. (NASDAQ: GRMN) may not be anywhere close to the old highs, but an analyst upgrade is helping it get close to challenging 52-week highs.

You can join our open email distribution list which goes out several times per week for top day trader alerts, top analyst upgrades and downgrades, IPO’s, key secondary offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG
SEPTEMBER 11, 2009

Posted on: September 11, 2009 – 9:03 am in After-Hours Activity, Pre-Market Activity, Trading Alert, , , , , ,

Top Analyst Downgrades (BLKB, CTXS, DSCO, EV, FII, LUV)

These are some of the analyst downgrades and cautious research calls we have seen early this Tuesday morning on Wall Street:

Blackbaud (BLKB) Cut to Hold at Jefferies.
Citrix Systems (CTXS) Cut to Perform at Oppenheimer.
Discovery Labs (DSCO) Cut to Underperform at Jefferies.
Eaton Vance (EV) Cut to Underweight at JPMorgan.
Federated Investors (FII) Cut to Underweight at JPMorgan.
Southwest Air (LUV) Cut to Sell at Argus.

JON C. OGG

Posted on: September 8, 2009 – 8:05 am in Analyst Calls, , , , , ,

Top Analyst Downgrades (CTXS, DSCO, EV, FII, FPL, RAX)

These are this Monday’s top pre-market analyst downgrades and cautious research calls from Wall Street with more than two hours until the market opens:

Citrix Systems (CTXS) Cut to Perform at Oppenheimer.
Discovery Labs (DSCO) Cut to Underperform at Jefferies.
Eaton Vance (EV) Cut to Underweight at JPMorgan.
Federated Investors (FII) Cut to Underweight at JPMorgan.
FPL Group (FPL) Cut to Underperform at Credit Suisse.
Rackspace (RAX) Cut to Neutral at Goldman Sachs.

JON C. OGG

Posted on: July 6, 2009 – 6:31 am in Analyst Calls, , , , , ,

Biotech Business Daily (CGRB, DSCO, EPIX, GSK, PSTI, VNDA)

Cougar Biotechnology, Inc. (NASDAQ: CGRB) is up over 5% in afternoon trading on the announcement that they will present a company update and clinical trial update at the Leerink Swann Cancer Roundtable Conference. Shares up $0.88 to $21.43. The 52-week range is $17.00 to $34.00.

Discovery Laboratories (NASDAQ: DSCO) shares are on roller coaster ride as they anticipate the await approval for Surfaxin, a preventative medicine for respiratory distress syndrome in premature infants. Last Friday, the stock dropped 50% after the FDA wrote an Approvable Letter to Discovery requesting more information. Today it is up 33% after Discovery announced that additional clinical trials will not be necessary. Shares are trading at $1.87 on extremely high relative trading volume. The 52-week range is $1.29 to $3.75.

EPIX Pharmaceuticals (NASDAQ: EPIX) announced the mid-stage human clinical trial launch of Alzheimer’s treatment, PRX-03140, making it eligible for a milestone payment of $7.5 million from GlaxoSmithKline (NYSE: GSK). Shares are up over 8% to $1.80. The 52-week range is $1.28 to $6.70.

Pluristem Therapeutics, Inc. (NASDAQ: PSTI) shares are down over 13% today on no new relevant news. Shares are down $0.63 to $3.96. The 52-week range is $1.52 to $28.00.

Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) shares are up almost 40% today after reporting narrower first quarter losses last Thursday, beating expectations. Also, Caris initiated coverage on the company with a “Buy” rating and a $22.00 price target, specifically citing the expectation that schizophrenia treatment Fanapta, will gain regulatory approval in July. Today, shares are up $1.68 to $5.89. The 52-week range is $2.70 to $22.49.

Rachel Lopez
May 5, 2008

Posted on: May 5, 2008 – 1:51 pm in Biotech, , , , , ,

Biotech Business Daily (BTRX, BMRN, DSCO, ENDP, MNKD, MIPI, QSC, TECH)

Today almost feels like the "March of Biotech-inguins" because most of the movers were small companies you might otherwise miss.  Here were the big movers:

  • Barrier Therapeutics (NASDAQ: BTRX) ran way up after first quarter results reported yesterday showed a 207% increase in revenues from last year at $8.4 million, driven by growth in sales of Vusion and Xolegel. Shares closed up 18% at $2.29 on a 52-week range of $1.90 to $7.60.
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) showed a first quarter positive profit or $0.02 EPS on a net income of $1.7 million. Analysts expected losses of $0.05 EPS. Earnings were driven primarily by sales of enzyme replacement therapy Naglazyme. Shares closed up almost 8% at $36.46. The 52-week range is $15.99 to $41.00.
  • Discovery Labs (NASDAQ: DSCO) trading up in anticipation of FDA approval for lung surfactant, Surfaxin, a treatment for premature infants suffering from respiratory distress. The company communicated confidence that any regulatory concerns have been ironed out and this third FDA result will be positive. Shares rose 17% to $2.87. The 52-week range is $1.75 to $3.75.
  • Endo Pharmaceuticals (NASDAQ: ENDP) settled a proxy battle with shareholder D.E. Shaw by nominating William Spangler to the board. They posted earnings today showing a net income of $59.53 and $0.44 EPS. Shares closed down 0.7% at $24.83. The 52-week range is $22.62 to $35.85.
  • Mannkind Corporation (NASDAQ: MNKD) up over 16% in anticipation of earnings release Monday. Shares up $0.37 at $2.60 at the close. The 52-week range is $1.86 to $14.71.
  • Molecular Insight Pharma (NASDAQ: MIPI) up almost 7% today on no news, although some just may be the thin volume and wide bid/ask spread. The oncology molecular imaging pharmaceutical company is sitting at $7.83 on a 52-week range of $5.66 to $12.95.
  • Questcor (AMEX: QSC) down despite posting strong first quarter results showing a positive net income of $6.5 million compared to a loss of $3.8 in first quarter 2007. The company also amended agreement Acthar distribution discount prices, positively impacting Questcor cash flows. Shares closed down 2.5% at $4.24. The 52-week range is $0.21 to $6.60.
  • Techne Corp. (NASDAQ: TECH) up after third quarter profit jumped 24% to $29.6 million or $0.76 EPS, beating estimates. Shares closed at $72.52, up 1%, on a 52-week range of $54.49 to $72.00.

Rachel Lopez
April 30, 2008

Posted on: April 30, 2008 – 3:21 pm in Biotech, Newsletter, , , , , , , ,

Biotech Movers & Shakers (FOLD, BAX, CYTK, DSCO, HALO, IMCL, SGEN)

Amicus Therapeutics (NASDAQ: FOLD) had a late afternoon surge, up 7% to $10.73. The 52 week range is $9.00 to $18.22.

Baxter International (NYSE: BAX)—contaminant in recalled Heparin identified by the FDA today. Shares rose slightly to $58.18 in response to board approved $2 billion stock buyback program. maybe it’s a major drug stock, but this has been a pending issue for some time.

Cytokinetics Inc. (NASDAQ: CYTK) up almost 10% to $3.38 today; annual report filed last week.

Discovery Laboratories Inc. (NASDAQ: DSCO) up over 10% today to $2.38 on a late afternoon rise on no new news.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) up 23% today to $6.06 on heavy late afternoon trading volume and no news. Halozyme dipped earlier this week due to downgrades.

ImClone Systems (NASDAQ: IMCL) showed little response to upgrades in anticipation to cancer clinical trial data. Shares inched up $0.20 to $43.30.

Seattle Genetics Inc. (NASDAQ: SGEN) upgraded by RBC Capital Markets and noted for strong research platform. Up 4% to $8.70. The 52-week range is $7.20 to $3.44.

Rachel Lopez
March 19, 2008

Posted on: March 19, 2008 – 3:56 pm in Biotech, , , , , , ,

Unusual Biotech Movers (DSCO, GNTA, IDMI, DDSS, POTP, DARA)

Discovery Laboratories Inc. (NASDAQ: DSCO) shares are up after a report that their drug Surfaxin, a respiratory distress syndrome treatment for premature infants, should gain FDA approval by May. In pre-market trading, the shares rose 6% to $2.08. Since opening, shares are up almost 13% to $2.21 in mid-morning trading. The 52 week range is $1.75 to $3.75.

Genta Incorporated (NASDAQ: GNTA) shares are down over 22% to $0.53 per share after news this morning that they have entered into an agreement to sell 6 million shares of common stock to institutional investors for $3.1 million in proceeds.

IDM Pharma, Inc. (NASDAQ: IDMI) shares are recovering today after last week’s plunge due to a delisting threat from the Nasdaq Stock Market. The company has until August 4, 2008 to close at over $1 for 10 consecutive days. Shares are up over 30% this morning to $2.20. The 52 week range is $0.57 to $10.75.

Labopharm Inc. (NASDAQ: DDSS) shares continue to rise after Friday’s announcement that late-stage clinical trials for Trazodone once-daily antidepressant showed improvement in patients’ quality of sleep. The drug has FDA approval for a twice-daily treatment and the company expects to apply for the FDA approval of the once-daily version later this year. Shares are up over 15% in early morning trading to $2.68.

Stockholder approval for Point Therapeutics, Inc. (NASDAQ: POTP) pending merger with DARA BioSciences, Inc. is expected this afternoon. Assuming the merger closes February 12 as expected, the new entity will trade under “DARA” on Nasdaq. Shares rose up over $0.06 in early morning trading but have slipped back down to opening price ranges to $0.14 in mid-day trading on relatively high trading volume.

Rachel Lopez
February 11, 2008

Posted on: February 11, 2008 – 10:59 am in Biotech, , , , , ,

The 52-week Low Club (ADS)(IKN)

Alliance Data Systems (ADS) Deal for buy-out may be falling apart. Shares fall to $39.54 from 52-week high of $80.79.

Image Entertainment (DISK) Dispute with creditors. Drops to $1.04 from 52-week high of $4.50.

Discovery Laboratories (DSCO) Recently named a "death bed" stock by Motley Fool. Sells off to $1.75 from 52-week high of $3.75.

IKON Office (IKN) Rough quarterly numbers. Down to $8.35 from 52-week high of $16.11.

Douglas A. McIntyre

Read More »

Posted on: January 28, 2008 – 4:04 pm in HI/LOW, , , ,

Pre-Market Stock News (June 7, 2007)

(A) Agilent reiterated guidance after completing Stratagene buyout.
(ADCT) ADC Telecom trading up 3% after posting $0.35 EPS vs $0.24 estimates.
(ANN) Ann Taylor May s-s-s -4.6% versus -3.1% estimate.
(ATVI) Activision will take $66.7 million non-cash and pre-tax charge for options back-dating.
(BEBE) Bebe Stroes May s-s-s -3% versus -2.8% estimate.
(BHI) Baker Hughes rig count rose 23 to 1,007 versus April and up from 920 in May 2006.
(BMET) Biomet’s private equity buyout raised to $46.00.
(CALL) CallWave announced the ‘industry’s first’ Visual Voicemail gadget for Google Personalized Homepage.
(CHINA) CDC Corp. appointed two new directors.
(COST) CostCo s-s-s were +7% in May, above 5.5% estimates.
(DJ) Dow Jones may have some interest from owner of Philadelphia Inquirer.
(DSCO) Discovery Laboratories initiated a Phase II clinical trial evaluating the use of Surfaxin in children up to two years of age suffering from Acute Respiratory Failure.
(ESLT) Elbit Systems awarded $110 million order by Thales UK to provide ISTAR capability for UK armed forces.
(FINL) Finish Line guided Q1 earnings below estimates and now sees a loss.
(HGSI) Human Genome Sciences shows positive final results Of Phase 2b trial of Albuferon
(IDEV) Indevus Pharmaceuticals reports positive data from Phase III NEBIDO trial for development for the treatment of male hypogonadism.
(INFN) Infinera Corp. IPO priced 14M shares at $13.00, above the 410.00 to $12.00 range.
(IMMC) Immunicon has released highlights from podium presentations made at ASCO meeting.
(JOSB) Jos. A. Banks may s-s-s +13.5% versus +4% estimate.
(JCP) JC Penney May s-s-s -2% vs +0.3% estimates.
(JWN) JW Nordstrom’s May s-s-s +6.3% versus +2.6% estimate.
(LTD) Limited Brands May s-s-s _2% vs -1% estimate.
(MSFT) Microsoft has entered a cross license pact with LG Electronics for further development of current and future product lines.
(OPTT) Ocean Power Tech awarded a $1.7 million Navy order for its PowerBuoys.
(SFD) Smithfield Foods $0.34 EPS vs $0.34e; named new CFO.
(SHRP) Sharper Image May s-s-s -8% vs -13% estimate.
(UTIW) UTI Worldwide $0.18 EPS vs $0.16e.
(WMT) Wal-Mart s-s-s +1.1% vs 1.2% estimate; sales were +1.3% after fuel.
(YANB) Yardville National gets $35.00 buyout from PNC.

Jon C. Ogg
June 7, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 7, 2007 – 7:20 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , , , , , , , , , , ,